{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:24:20Z","timestamp":1791606260492,"version":"4.3.4"},"reference-count":42,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the nasal and paranasal sinus mucosa, associated with significant impairment in quality of life, frequent postoperative recurrence, and repeated need for systemic glucocorticosteroid therapy. Despite the availability of biologics targeting IL-4\/IL-13, IL-5, and IgE, a subset of patients shows incomplete or insufficient clinical response. In this context, upstream targeting of epithelial alarmins, particularly thymic stromal lymphopoietin (TSLP), has emerged as a potential therapeutic strategy. To critically review current evidence on the role of TSLP in CRSwNP and to evaluate available data on the mechanism of action, clinical efficacy, and therapeutic potential of tezepelumab in severe and recurrent disease. Materials and Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science. Studies published between 2016 and 2026 were included, comprising experimental research, phase II\u2013III clinical trials, systematic reviews, and international guidelines. Results: TSLP functions as an epithelial alarmin that initiates and amplifies type 2 inflammation via dendritic cell activation, Th2 polarization, and activation of type 2 innate lymphoid cells (ILC2). Data suggests that tezepelumab, a monoclonal antibody targeting TSLP, may reduce inflammation and regulate the immune system. Evidence from asthma populations and relevant CRSwNP subgroups indicates potential improvements in nasal polyp score, congestion, olfactory function and quality of life. It is our understanding that the safety profile appears comparable to placebo, with no new safety concerns having been identified in long-term studies. Conclusions: Tezepelumab is a promising biologic that targets inflammation in CRSwNP. It may benefit severe, recurrent, treatment-resistant disease by modulating immune pathways. However, evidence is indirect and limited, and more trials are needed to define its efficacy, identify biomarkers, and clarify its role in treatment algorithms.<\/jats:p>","DOI":"10.3390\/medicina62071423","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:48:28Z","timestamp":1784717308000},"page":"1423","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tezepelumab in Chronic Rhinosinusitis with Nasal Polyps: Pathophysiology, Clinical Evidence, and Therapeutic Perspectives"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-4299","authenticated-orcid":false,"given":"Bayan","family":"Aigozhina","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rais","family":"Tulebaeyv","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talapbek","family":"Azhenov","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serik","family":"Dzhandayev","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Papulova","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rano","family":"Zhankina","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Astana Medical University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7603-688X","authenticated-orcid":false,"given":"Kalamkas","family":"Sagandykova","sequence":"additional","affiliation":[{"name":"\u201cUniversity Medical Center\u201d Corporate Fund, School of Medicine, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: Rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin. Otolaryngol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/alr.22487","article-title":"Revision surgery rates in chronic rhinosinusitis with nasal polyps: Meta-analysis of risk factors","volume":"10","author":"Loftus","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/alr.22505","article-title":"Factors impacting revision surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"10","author":"Loftus","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_7","first-page":"45","article-title":"Nasal polyps in patients with asthma: Prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dekeyser, A., Huart, C., Hummel, T., and Hox, V. (2024). Olfactory Loss in Rhinosinusitis: Mechanisms of Loss and Recovery. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084460"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/JAA.S372598","article-title":"Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial","volume":"16","author":"Maspero","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2473974X221128930","DOI":"10.1177\/2473974X221128930","article-title":"Elucidating the Real-World Burden of Chronic Rhinosinusitis With Nasal Polyps in Patients in the USA","volume":"6","author":"Benson","year":"2022","journal-title":"OTO Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e36024","DOI":"10.1097\/MD.0000000000036024","article-title":"Research progress of glucocorticoid resistance in chronic rhinosinusitis with nasal polyps: A review","volume":"102","author":"Chen","year":"2023","journal-title":"Medicine"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, Y.S., Feng, C.Y., Su, S.H., Wang, Y.H., Yang, T.H., and Lin, C.F. (2025). Recurrence of Chronic Rhinosinusitis with Nasal Polyps After Surgery: Risk Factors, Predictive Models, and Treatment Approaches with a Focus on Western and Asian Differences. Medicina, 61.","DOI":"10.3390\/medicina61091620"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2500\/aap.2025.46.250050","article-title":"The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps","volume":"46","author":"Peters","year":"2025","journal-title":"Allergy Asthma Proc."},{"key":"ref_15","first-page":"290","article-title":"Targeted biologics for chronic rhinosinusitis with nasal polyps: Efficacy and safety comparison of eight monoclonal antibodies via network meta-analysis","volume":"64","author":"Wang","year":"2026","journal-title":"Rhinology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jaip.2020.03.007","article-title":"Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications","volume":"8","author":"Bachert","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","article-title":"Endotype-driven care pathways in patients with chronic rhinosinusitis","volume":"141","author":"Bachert","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jaci.2017.09.009","article-title":"Chronic rhinosinusitis in Asia","volume":"140","author":"Zhang","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaci.2025.02.015","article-title":"New insights into the endotypes of chronic rhinosinusitis in the biologic era","volume":"156","author":"Wang","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/all.16499","article-title":"Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence","volume":"80","author":"Cai","year":"2025","journal-title":"Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","article-title":"Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps","volume":"155","author":"Kratchmarov","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.anai.2018.10.014","article-title":"Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes","volume":"122","author":"Cao","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/alr.22774","article-title":"Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study","volume":"11","author":"Bajpai","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yang, C., Guo, L., Wang, Y., Jiang, W., Chen, S., and Gu, Q. (2025). The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis. Front. Allergy, 6, Erratum in Front. Allergy\u00a02025, 6, 1679519. https:\/\/doi.org\/10.3389\/falgy.2025.1679519.","DOI":"10.3389\/falgy.2025.1599797"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"uxaf041","DOI":"10.1093\/cei\/uxaf041","article-title":"Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps","volume":"219","author":"Peters","year":"2025","journal-title":"Clin. Exp. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jaci.2013.04.005","article-title":"Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis","volume":"132","author":"Nagarkar","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2016.06.066","article-title":"Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps","volume":"139","author":"Chen","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Whetstone, C.E., Ranjbar, M., Omer, H., Cusack, R.P., and Gauvreau, G.M. (2022). The Role of Airway Epithelial Cell Alarmins in Asthma. Cells, 11.","DOI":"10.3390\/cells11071105"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Duchesne, M., Okoye, I., and Lacy, P. (2022). Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.975914"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2022.07.003","article-title":"TSLP, IL-33, and IL-25: Not just for allergy and helminth infection","volume":"150","author":"Stanbery","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ha, J.-G., and Cho, H.-J. (2023). Unraveling the Role of Epithelial Cells in the Development of Chronic Rhinosinusitis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814229"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/alr.22206","article-title":"Sentinels at the wall: Epithelial-derived cytokines serve as triggers of upper airway type 2 inflammation","volume":"9","author":"Patel","year":"2019","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Papacharalampous, G.X., Deftereou, T.E., Chaidas, K., Vlastarakos, P.V., Constantinidis, J., and Katotomichelakis, M. (2026). The Use of Biomarkers to Justify the Choice of the Proper Biologic Agent for the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review. Medicina, 62.","DOI":"10.3390\/medicina62061188"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e19249","DOI":"10.1016\/j.heliyon.2023.e19249","article-title":"Pathogenesis of chronic rhinosinusitis with nasal polyp and a prominent T2 endotype","volume":"9","author":"Shah","year":"2023","journal-title":"Heliyon"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12964-022-00839-x","article-title":"The role of Staphylococcus aureus enterotoxin B in chronic rhinosinusitis with nasal polyposis","volume":"20","author":"Chegini","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101633","DOI":"10.1016\/j.bjorl.2025.101633","article-title":"Long-term efficacy and safety of different biologics in treatment of chronic rhinosinusitis with nasal polyps: A network meta-analysis","volume":"91","author":"Chen","year":"2025","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Book, R., Lazutkin, A., and Eliashar, R. (2025). Long-Term Real-World Outcomes and Insights of Biologic Therapies in Chronic Rhinosinusitis with Nasal Polyps. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104694"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"250186","DOI":"10.1183\/16000617.0186-2025","article-title":"Efficacy of biologic agents in patients with comorbid asthma and chronic rhinosinusitis with nasal polyps: A systematic review and meta-analysis of randomised controlled trials","volume":"35","author":"Kyriakopoulos","year":"2026","journal-title":"Eur. Respir. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: A systematic review","volume":"56","author":"Tsetsos","year":"2017","journal-title":"Rhinol. J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1423\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:17:49Z","timestamp":1785147469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071423"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071423","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}